Microvascular Modifications in Diabetic Retinopathy

被引:167
作者
Durham, Jennifer T. [1 ,2 ]
Herman, Ira M. [1 ,2 ]
机构
[1] Tufts Univ, Sackler Sch Grad Biomed Sci, Program Cellular & Mol Physiol, Dept Mol Physiol & Pharmacol, Boston, MA 02111 USA
[2] Tufts Univ, Ctr Innovat Wound Healing Res, Boston, MA 02111 USA
关键词
Angiogenesis; Endothelial cell; Pericyte; Cytoskeleton; VEGF; Adenovirus/AAV; PEDF; PPE1; Microvascular modifications; Diabetic retinopathy; ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; INTRAVITREAL BEVACIZUMAB AVASTIN; VASCULAR-PERMEABILITY FACTOR; MEDIATED GENE-TRANSFER; SINGLE-CHAIN DIABODY; PROTEIN-KINASE-C; RETINAL NEOVASCULARIZATION; CHOROIDAL NEOVASCULARIZATION; TUMOR-CELLS;
D O I
10.1007/s11892-011-0204-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients struggling with diabetes are at elevated risks for several sight-threatening diseases, including proliferative diabetic retinopathy (DR). DR manifests in two stages: first, the retinal microvasculature is compromised and capillary degeneration occurs; subsequently, an over-compensatory angiogenic response is initiated. Early changes in the retinal microcirculation include disruptions in blood flow, thickening of basement membrane, eventual loss of mural cells, and the genesis of acellular capillaries. Endothelial apoptosis and capillary dropout lead to a hypoxic inner retina, alterations in growth factors, and upregulation of inflammatory mediators. With disease progression, pathologic angiogenesis generates abnormal preretinal microvessels. Current therapies, which include panretinal photocoagulation and vitrectomy, have remained unaltered for several decades. With several exciting preclinical advances, emergent technologies and innovative cellular targets may offer newfound hope for developing "next-generation" interventional or preventive clinical approaches that will significantly advance current standards of care and clinical outcomes.
引用
收藏
页码:253 / 264
页数:12
相关论文
共 160 条
  • [1] HUMAN BASIC FIBROBLAST GROWTH-FACTOR - NUCLEOTIDE-SEQUENCE AND GENOMIC ORGANIZATION
    ABRAHAM, JA
    WHANG, JL
    TUMOLO, A
    MERGIA, A
    FRIEDMAN, J
    GOSPODAROWICZ, D
    FIDDES, JC
    [J]. EMBO JOURNAL, 1986, 5 (10) : 2523 - 2528
  • [2] Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals
    Adamis, AP
    Altaweel, M
    Bressler, NM
    Cunningham, ET
    Davis, MD
    Goldbaum, M
    Gonzales, C
    Guyer, DR
    Katz, B
    Patel, M
    [J]. OPHTHALMOLOGY, 2006, 113 (01) : 23 - 28
  • [3] VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS
    AIELLO, LP
    AVERY, RL
    ARRIGG, PG
    KEYT, BA
    JAMPEL, HD
    SHAH, ST
    PASQUALE, LR
    THIEME, H
    IWAMOTO, MA
    PARK, JE
    NGUYEN, HV
    AIELLO, LM
    FERRARA, N
    KING, GL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) : 1480 - 1487
  • [4] [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
  • [5] Diabetic retinopathy - Seeing beyond glucose-induced microvascular disease
    Antonetti, David A.
    Barber, Alistair J.
    Bronson, Sarah K.
    Freeman, Willard M.
    Gardner, Thomas W.
    Jefferson, Leonard S.
    Kester, Mark
    Kimball, Scot R.
    Krady, J. Kyle
    LaNoue, Kathryn F.
    Norbury, Christopher C.
    Quinn, Patrick G.
    Sandirasegarane, Lakshman
    Simpson, Ian A.
    [J]. DIABETES, 2006, 55 (09) : 2401 - 2411
  • [6] Intravitreal Bevacizumab (Avastin (R)) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture
    Arevalo, J. Fernando
    Sanchez, Juan G.
    Lasave, Andres F.
    Wu, Lihteh
    Maia, Mauricio
    Bonafonte, Sergio
    Brito, Miguel
    Alezzandrini, Arturo A.
    Restrepo, Natalia
    Berrocal, Maria H.
    Saravia, Mario
    Farah, Michel E.
    Fromow-Guerra, Jans
    Morales-Canton, Virgilio
    [J]. CURRENT DIABETES REVIEWS, 2010, 6 (05) : 313 - 322
  • [7] Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents
    Auricchio, A
    Behling, KC
    Maguire, AM
    O'Connor, EE
    Bennett, J
    Wilson, JM
    Tolentino, MJ
    [J]. MOLECULAR THERAPY, 2002, 6 (04) : 490 - 494
  • [8] Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
    Avery, RL
    Pieramici, DJ
    Rabena, MD
    Castellarin, AA
    Nasir, MA
    Giust, MJ
    [J]. OPHTHALMOLOGY, 2006, 113 (03) : 363 - 372
  • [9] Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy
    Avery, Robert L.
    Pearlman, Joel
    Pieramici, Dante J.
    Rabena, Melvin D.
    Castellarin, Alessandro A.
    Nasir, Ma'an A.
    Giust, Matthew J.
    Wendel, Robert
    Patel, Arun
    [J]. OPHTHALMOLOGY, 2006, 113 (10) : 1695 - 1705
  • [10] Novel challenges in exploring peptide ligands and corresponding tissue-specific endothelial receptors
    Balestrieri, Maria Luisa
    Napoli, Claudio
    [J]. EUROPEAN JOURNAL OF CANCER, 2007, 43 (08) : 1242 - 1250